| Literature DB >> 36014769 |
Jihyun Eom1, Bugyeong Son2, Seung Hyun Kim2,3, Yongsoon Park1.
Abstract
Antioxidant intake has been suggested to be associated with the prognosis of amyotrophic lateral sclerosis (ALS). This study aimed to investigate whether dietary total antioxidant capacity (DTAC) and that of major food groups are related to disease progression rate (ΔFS) and survival time in ALS patients. A total of 301 participants diagnosed with sporadic ALS according to the revised El Escorial criteria were recruited from March 2011 and followed up to the event occurrence, or the end of October 2021. Events included percutaneous endoscopic gastrostomy, tracheostomy, and death. DTAC was estimated using task automation and an algorithm based on 24 h dietary recall. ΔFS was negatively correlated with the vegetable and legume DTAC, and event-free survival was different among the tertiles of vegetables and legumes DTAC. Consistently, the risk of events was negatively associated with DTAC from vegetables and legumes. These results suggest that the intake of antioxidants, especially those derived from vegetables and legumes, has a beneficial effect on delaying disease progression and prolonging survival in patients with ALS. Further studies with large prospective cohorts and clinical trials are needed to determine whether the consumption of foods with high DTAC improves the prognosis of ALS.Entities:
Keywords: amyotrophic lateral sclerosis; dietary total antioxidant capacity; disease progression rate; event-free survival
Mesh:
Substances:
Year: 2022 PMID: 36014769 PMCID: PMC9414183 DOI: 10.3390/nu14163264
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Flow chart for the selection of participants with amyotrophic lateral sclerosis (ALS).
Demographics and clinical features of the participants according to tertiles of dietary total antioxidant capacity (DTAC) 1.
| Variables | Total ( | Tertiles of Total DTAC (mg VCE/d) | |||
|---|---|---|---|---|---|
| Total T1 ( | Total T2 ( | Total T3 ( | |||
| DTAC (mg VCE/d) | 358.23 ± 256.94 | 127.82 ± 62.29 3a | 307.97 ± 50.22 b | 639.42 ± 239.91 c | <0.001 |
| Type of endpoint, | 0.539 | ||||
| PEG | 90 (29.9) | 33 (33.0) | 31 (30.7) | 26 (26.0) | |
| Tracheostomy | 47 (15.6) | 17 (17.0) | 14 (13.9) | 16 (16.0) | |
| Death | 37 (12.3) | 9 (9.0) | 12 (11.9) | 16 (16.0) | |
| Age at symptom onset (y) | 54.64 ± 10.43 | 55.69 ± 11.10 | 54.11 ± 10.20 | 54.12 ± 9.98 | 0.384 |
| Sex, male, | 158 (52.5) | 54 (54.0) | 54 (53.5) | 50 (50.0) | 0.828 |
| Bulbar onset, | 66 (21.9) | 26 (26.0) | 15 (14.9) | 25 (25.0) | 0.107 |
| Symptom duration (months) 4 | 15.30 ± 4.91 | 16.12 ± 4.63 | 15.16 ± 5.22 | 14.62 ± 4.79 | 0.102 |
| ΔFS 5 | 0.75 ± 0.46 | 0.81 ± 0.47 | 0.73 ± 0.45 | 0.71 ± 0.46 | 0.203 |
| ALSFRS-R score (0–48) | 37.35 ± 6.23 | 35.84 ± 6.70 3a | 37.83 ± 5.70 ab | 38.38 ± 6.01 b | 0.005 |
| Bulbar score (0–12) | 9.97 ± 1.97 | 9.60 ± 2.08 | 10.18 ± 1.88 | 10.12 ± 1.90 | 0.062 |
| BMI (kg/m2) | 22.68 ± 2.88 | 22.14 ± 2.99 | 22.94 ± 2.61 | 22.96 ± 2.96 | 0.068 |
| Exercise, | 197 (65.4) | 54 (54.0) | 73 (72.3) | 70 (70.0) | 0.012 |
| Sun exposure, | 0.008 | ||||
| Never | 79 (26.2) | 39 (39.0) | 21 (20.8) | 19 (19.0) | |
| <30 min | 87 (28.9) | 25 (25.0) | 34 (33.7) | 28 (28.0) | |
| ≥30 min | 135 (44.9) | 36 (36.0) | 46 (45.5) | 53 (53.0) | |
| Smoking, | 109 (36.2) | 33 (33.0) | 41 (40.6) | 35 (35.0) | 0.509 |
| Drinking, | 144 (47.8) | 52 (52.0) | 50 (49.5) | 42 (42.0) | 0.337 |
| Treated with riluzole, | 270 (89.7) | 89 (89.0) | 90 (89.1) | 91 (91.0) | 0.391 |
| Treated with edaravone, | 32 (10.7) | 10 (10.0) | 14 (13.9) | 8 (8.0) | 0.872 |
VCE, vitamin C equivalent; PEG, percutaneous endoscopic gastrostomy; ΔFS, disease progression rate; ALSFRS-R, amyotrophic lateral sclerosis functional rating scale-revised; BMI, body mass index. 1 Values are presented as mean ± SD or number of participants (percentage distribution), as appropriate. 2 p-values were calculated using the Kruskal–Wallis test for DTAC, age at symptom onset, time point of dietary survey from symptom onset, ASLFRS-R score, and ΔFS or one-way ANOVA for BMI, followed by Bonferroni’s post hoc test for continuous variables. 3 Values with different superscript letters (i.e., a, b, c) in the same row are significantly different at p < 0.05, according to the ranked ANOVA with Bonferroni’s post hoc test. 4 Symptom duration (months) refers to the time point of the dietary survey from symptom onset. 5 ΔFS was calculated using the following formula: ΔFS = (48 − ALSFRS-R score at the time of survey/duration from symptom onset to the time of the survey (months)).
Demographics and clinical features of the participants according to tertiles of the dietary total antioxidant capacity (DTAC) of major food groups 1.
| Variables | T1 ( | T2 ( | T3 ( | |
|---|---|---|---|---|
| Fruit DTAC (mg VCE/Day) | ||||
| ≤12.62 | 12.63–126.55 | >126.55 | ||
| Age at symptom onset (year) | 53.86 ± 11.76 | 55.67 ± 10.32 | 54.37 ± 9.05 | 0.447 |
| Sex, male, | 61 (61.0) | 53 (52.5) | 44 (44.0) | 0.055 |
| Bulbar onset, | 20 (20.0) | 21 (20.8) | 25 (25.0) | 0.562 |
| Symptom duration (months) 4 | 15.93 ± 4.88 | 15.46 ± 5.06 | 14.51 ± 4.72 | 0.101 |
| ΔFS 5 | 0.68 ± 0.42 3a | 0.82 ± 0.45 b | 0.75 ± 0.51 b | 0.033 |
| ALSFRS-R score (0–48) | 37.85 ± 6.41 | 36.24 ± 6.10 | 37.98 ± 6.07 | 0.086 |
| Bulbar score (0–12) | 10.13 ± 2.03 | 9.80 ± 2.09 | 9.97 ± 1.77 | 0.499 |
| Vegetable DTAC (mg VCE/day) | ||||
| ≤83.92 | 83.93–170.06 | >170.06 | ||
| Age at symptom onset (year) | 54.17 ± 10.18 | 56.27 ± 9.88 | 53.46 ± 11.09 | 0.139 |
| Sex, male, | 56 (56.0) | 49 (48.5) | 53 (53.0) | 0.564 |
| Bulbar onset, | 21 (21.0) | 24 (23.8) | 21 (21.0) | 0.959 |
| Symptom duration (months) 4 | 14.62 ± 4.46 | 15.99 ± 5.03 | 15.28 ± 5.15 | 0.132 |
| ΔFS 5 | 0.93 ± 0.49 3a | 0.70 ± 0.41 b | 0.62 ± 0.42 b | <0.001 |
| ALSFRS-R score (0–48) | 35.24 ± 6.78 3a | 37.66 ± 5.59 b | 39.15 ± 5.67 b | <0.001 |
| Bulbar score (0–12) | 9.69 ± 2.01 | 9.88 ± 1.83 | 10.33 ± 2.02 | 0.061 |
| Legume DTAC (mg VCE/day) | ||||
| ≤15.26 | 15.27–53.89 | >53.89 | ||
| Age at symptom onset (year) | 55.97 ± 9.36 | 54.61 ± 11.64 | 53.33 ± 10.07 | 0.202 |
| Sex, male, | 54 (54.0) | 48 (47.5) | 56 (56.0) | 0.453 |
| Bulbar onset, | 22 (22.0) | 21 (20.8) | 23 (23.0) | 0.911 |
| Symptom duration (months) 4 | 14.99 ± 4.42 | 15.62 ± 5.06 | 15.28 ± 5.23 | 0.658 |
| ΔFS 5 | 0.83 ± 0.50 3a | 0.76 ± 0.47 ab | 0.65 ± 0.39 b | 0.020 |
| ALSFRS-R score (0–48) | 36.09 ± 7.07 3a | 37.20 ± 6.09 ab | 38.77 ± 5.13 b | 0.016 |
| Bulbar score (0–12) | 9.70 ± 2.18 | 9.91 ± 1.74 | 10.29 ± 1.93 | 0.058 |
VCE, vitamin C equivalent; ΔFS, disease progression rate; ALSFRS-R, amyotrophic lateral sclerosis functional rating scale-revised. 1 Values are presented as mean ± SD or number of participants (percentage distribution), as appropriate. 2 p-values were calculated using the Kruskal–Wallis test for DTAC, time point of dietary survey from symptom onset, ASLFRS-R score, and ΔFS or one-way ANOVA for age at symptom onset, followed by Bonferroni’s post hoc test for continuous variables. 3 Values with different superscript letters (i.e., a, b) in the same row are significantly different at p < 0.05, according to the ranked ANOVA with Bonferroni’s post hoc test. 4 Symptom duration (months) refers to the time point of the dietary survey from symptom onset. 5 ΔFS was calculated using the following formula: ΔFS = (48 − ALSFRS-R score at the time of survey/duration from symptom onset to the time of the survey (months)).
Figure 2Association between dietary total antioxidant capacity (DTAC) and disease progression rate (ΔFS). The correlation between DTAC and ΔFS was determined by Spearman’s rank correlation coefficients.
Figure 3Kaplan–Maier survival curves showing 60-month survival according to the tertiles of the dietary total antioxidant capacity (DTAC). Statistical significance was determined using the log-rank test and the Kaplan–Meier method. * p < 0.05, ** p < 0.01.
Figure 4Cox proportional hazards regression analysis of event status in participants with amyotrophic lateral sclerosis (ALS) according to the tertiles of dietary total antioxidant capacity (DTAC). The adjusted hazard ratio (HR) and 95% confidence interval (CI) were determined by Cox proportional hazards regression analysis after adjusting for the age at symptom onset, sex, body mass index, onset site, disease progression rate, and energy intake.